Patents by Inventor Roy A. Black

Roy A. Black has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140228540
    Abstract: The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.
    Type: Application
    Filed: April 22, 2014
    Publication date: August 14, 2014
    Applicant: Amgen Inc.
    Inventors: Roy A. Black, Peng Li, Joshua Silverman
  • Publication number: 20120231013
    Abstract: The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.
    Type: Application
    Filed: July 29, 2010
    Publication date: September 13, 2012
    Inventors: Roy A. Black, Peng Li, Joshua Silverman, Chadwick T. King
  • Patent number: 7695948
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: April 13, 2010
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Publication number: 20090247605
    Abstract: This invention relates to the identification of membrane-associated proteins shed by metalloproteinases and in particular by TNF-alpha converting enzyme (TACE), to the use of such metalloproteinase-shed proteins in assays for TACE agonists and antagonists, and to the use of metalloproteinase agonists and antagonists, and particularly TACE agonists and antagonists, in the treatment of diseases mediated by certain shed proteins.
    Type: Application
    Filed: June 28, 2007
    Publication date: October 1, 2009
    Applicant: Immunex Corporation
    Inventors: Richard S. Johnson, Lin Guo, Jacques J. Peschon, Roy A. Black, Rajeev M. Mahimkar
  • Publication number: 20080160571
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Application
    Filed: February 21, 2007
    Publication date: July 3, 2008
    Applicant: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Patent number: 7199224
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: April 3, 2007
    Assignee: Immunex Corporation
    Inventors: Roy A Black, Charles Rauch, Carl J March, Douglas P Cerretti
  • Publication number: 20060292144
    Abstract: Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities.
    Type: Application
    Filed: August 28, 2006
    Publication date: December 28, 2006
    Applicant: Immunex Corporation
    Inventors: Roy Black, Kurt Poindexter, Bruce Mosley, Robert DuBose, Steven Wiley
  • Publication number: 20060188474
    Abstract: There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1? and for a substrate comprising: R1-Asp-R2-R3 wherein R1 and R3 are independently any D or L isomer amino acid, R2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1? protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.
    Type: Application
    Filed: August 25, 2005
    Publication date: August 24, 2006
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Sleath, Roy Black, Shirley Kronheim
  • Publication number: 20060177443
    Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration, and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
    Type: Application
    Filed: March 28, 2006
    Publication date: August 10, 2006
    Applicant: Immunex Corporation
    Inventors: William Fanslow, Douglas Cerretti, Kurt Poindexter, Roy Black
  • Patent number: 7074408
    Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: July 11, 2006
    Assignee: Immunex Corporation
    Inventors: William C. Fanslow, III, Douglas P. Cerretti, Kurt M. Poindexter, Roy A. Black
  • Patent number: 6995141
    Abstract: There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1? and for a substrate comprising: R1—Asp—R2—R3 wherein R1 and R3 are independently any D or L isomer amino acid, R2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1? protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: February 7, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul R. Sleath, Roy A. Black, Shirley R. Kronheim
  • Publication number: 20050280550
    Abstract: A method and device for illuminating a lighting element include an input for receiving an electrical signal from a separate mobile device, a lighting element, a memory for storing a plurality of user-selectable lighting modes, and a processor. The processor illuminates the lighting elements according to both the selected lighting mode and the electrical signal received from the separate device. The separate device may be a digital audio player, and the processor may vary the intensity of mode-specific lighting according to the signal from the audio player. Further, the selected mode may cause a strobe or text message to be displayed when another signal indicates that a page or email has been received. The lighting element may be an LED, an array of them, or a display screen with pixel lighting elements.
    Type: Application
    Filed: September 23, 2004
    Publication date: December 22, 2005
    Inventors: Kerry Kurian, Roy Black
  • Patent number: 6842704
    Abstract: A tumor necrosis factor-? converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: January 11, 2005
    Assignees: Immunex Corporation, Max-Planck-Institute for Biochemistry, Wyeth
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Publication number: 20040265983
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: February 24, 2004
    Publication date: December 30, 2004
    Applicants: IMMUNEX CORPORATION; MAX-PLANCK-INSTITUTE FOR BIOCHEMISTRY, WYETH
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Publication number: 20040091473
    Abstract: Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities.
    Type: Application
    Filed: June 17, 2003
    Publication date: May 13, 2004
    Inventors: Robert F. DuBose, Steven R. Wiley, Roy A. Black
  • Publication number: 20040047854
    Abstract: Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities.
    Type: Application
    Filed: June 10, 2003
    Publication date: March 11, 2004
    Inventors: Roy A. Black, Kurt M. Poindexter, Bruce A. Mosley, Robert F. DuBose, Steven R. Wiley
  • Publication number: 20030175816
    Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Application
    Filed: April 25, 2003
    Publication date: September 18, 2003
    Applicant: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Publication number: 20030108959
    Abstract: This invention relates to the identification of membrane-associated proteins shed by metalloproteinases and in particular by TNF-alpha converting enzyme (TACE), to the use of such metalloproteinase-shed proteins in assays for TACE agonists and antagonists, and to the use of metalloproteinase agonists and antagonists, and particularly TACE agonists and antagonists, in the treatment of diseases mediated by certain shed proteins.
    Type: Application
    Filed: October 25, 2002
    Publication date: June 12, 2003
    Inventors: Richard S. Johnson, Lin Guo, Jacques J. Peschon, Roy A. Black, Rajeev M. Mahimkar
  • Patent number: 6555354
    Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: April 29, 2003
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Publication number: 20030004651
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: September 24, 2001
    Publication date: January 2, 2003
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin